125I粒子条联合胆道支架植入治疗恶性梗阻性黄疸22例疗效分析

【摘要】　 　目的 研究和探讨125I粒子条联合胆道支架植入治疗恶性梗阻性黄疸的临床疗效。方法 2011年6月—2013年9月收治恶性梗阻性黄疸患者40例。行胆道支架植入术治疗患者18例，为对照组；采用125I粒子条联合胆道支架植入患者22例，为观察组。两组均采用经皮肝穿刺胆道引流（PTCD）并胆道支架植入。结果 观察组与对照组的平均胆道开通时间分别为（8.7 ± 0.7）和（6.2 ± 0.4）个月，两组比较差异有统计学意义（P < 0.05）。观察组与对照组术后平均生存时间分别为（11.4 ± 0.8）和（8.7 ± 0.5）个月，生存时间的差异有统计学意义（P < 0.05）。术后近期疗效及并发症两组之间的比较无明显差异（P > 0.05），但是远期疗效有显著差异（P < 0.05）。结论 与对照组相比，观察组的术后生存时间及胆道开通时间明显延长，对于125I粒子条联合支架治疗恶性梗阻性黄疸值得进一步临床研究。
     

Enhance cycling performance of LiMn2O4 cathode by Sr2+ and Cr3+ doping

Spinel LiSr_0·1Cr_0·1Mn_1·8O₄ was synthesised by high temperature solid state method in order to enhance the electrochemical performance. The LiSr_0·1Cr_0·1Mn_1·8O₄ (LSCMO) materials were characterised by X-ray diffraction (XRD), scanning electron microscopy (SEM) and electrochemical tests. The XRD and SEM studies confirm that LSCMO had spinel crystal structure with a space group of Fd3m, and the particle of LSCMO shows irregular shape. The cyclic voltammetry data illustrated that the heavy current charge–discharge performance of LMO was improved by Sr²⁺ and Cr³⁺ doping. The galvanostatic charge–discharge of LSCMO cathode materials was measured at 1, 5, 10 and 20 C. The results indicated that LSCMO improved the capacity retention.